Date: 2013-08-08
Type of information: Grant
Company: Epistem (UK)
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: €1.5 million
Funding type: grant
Planned used: this grant will be used for the development of point-of-care Hepatitis C assays.
Others: Epistem has been awarded funding of €1.5m over a three year period by the European Commission\'s 7th Framework Programme. This is part of a €6.0m consortium project (Grant n° 601851) for the development of point-of-care Hepatitis C assays. The PoC-HCV consortium additionally consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Qlucore (Sweden) and Biosurfit (Portugal). The primary objective of the PoC-HCV consortium is to provide PoC diagnostic and predictive tests that enable tangible improvements in the health and quality of life of chronic Hepatitis C patients, while simultaneously helping to manage the rising cost of medical treatment.
Therapeutic area: Diagnostic - Infectious diseases
